{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:15:45Z","timestamp":1794935745393,"version":"4.9.1"},"reference-count":61,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Molecular measurable residual disease (MRD) assessment in patients with acute myeloid leukemia (AML) has been established for only a few specific markers: mutant NPM1 and FLT3 internal tandem duplication (ITD). Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are present in \u223c20% of patients with AML. However, validation of mutant IDH1\/2 MRD has been hampered by cohort size as well as the availability of highly sensitive and specific MRD detection assays. Here, we comprehensively investigate the impact of persistent IDH1\/2 mutations in complete remission after intensive chemotherapy in a cohort of 163 newly diagnosed patients with IDH-mutant AML, enrolled in Dutch-Belgian Cooperative Trial Group for Hematology-Oncology and Swiss Group for Clinical Cancer Research clinical trials, using a next-generation sequencing (NGS)\u2013based approach, targeting all hot spot mutations in IDH1 (R132) and IDH2 (R140 and R172). The high sensitivity (10\u20134) as well as the levels of persistent IDH1\/2 mutations detected by the NGS-based approach were confirmed by an independent super rolling circle amplification assay. We demonstrate that the risk of relapse was significantly increased in patients with AML with measurable persistent IDH2 mutations (P = .027; subdistribution hazard ratio (SHR), 2.34) but not in patients with persistent mutant IDH1 (P = .591; SHR, 0.80). Moreover, the association of persistence of mutant IDH2 and increased risk of relapse was most pronounced in patients with mutant IDH2 AML without concomitant NPM1 mutations or FLT3-ITD (P = .011; SHR, 5.29). Thus, mutant IDH2 appears as a potentially useful novel molecular MRD marker with prognostic significance in AML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016726","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:04:58Z","timestamp":1752786298000},"page":"4860-4869","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Utility of <i>IDH1\/2<\/i> mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2520-9817","authenticated-orcid":false,"given":"Emma L.","family":"Boertjes","sequence":"first","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4321-9104","authenticated-orcid":false,"given":"Christian M.","family":"Vonk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois G.","family":"Kavelaars","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7394-9191","authenticated-orcid":false,"given":"Marie","family":"Engvall","sequence":"additional","affiliation":[{"name":"2Rarity Bioscience, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Nordin","sequence":"additional","affiliation":[{"name":"2Rarity Bioscience, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-9338","authenticated-orcid":false,"given":"Lisanne","family":"Beugelink","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5781-3622","authenticated-orcid":false,"given":"Melissa","family":"Rijken","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolinda M. L.","family":"Konijnenburg","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-5217","authenticated-orcid":false,"given":"Bob","family":"L\u00f6wenberg","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. M.","family":"Valk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"9","key":"2025101409264083100_bib1","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2025101409264083100_bib2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"11","key":"2025101409264083100_bib3","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/leu.2015.91","article-title":"Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms","volume":"29","author":"Molenaar","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"2025101409264083100_bib4","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2025101409264083100_bib5","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2025101409264083100_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.exphem.2015.05.009","article-title":"Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis","volume":"43","author":"Eriksson","year":"2015","journal-title":"Exp Hematol"},{"issue":"19","key":"2025101409264083100_bib7","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis","volume":"7","author":"Zarnegar-Lumley","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2025101409264083100_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"issue":"7300","key":"2025101409264083100_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09132","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"465","author":"Dang","year":"2010","journal-title":"Nature"},{"issue":"6","key":"2025101409264083100_bib10","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3390\/biomedicines10061359","article-title":"2-hydroxyglutarate in acute myeloid leukemia: a journey from pathogenesis to therapies","volume":"10","author":"Raimondi","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"2025101409264083100_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5045\/br.2021.2021152","article-title":"IDH1\/2 mutations in acute myeloid leukemia","volume":"57","author":"Byun","year":"2022","journal-title":"Blood Res"},{"issue":"22","key":"2025101409264083100_bib12","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025101409264083100_bib13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2025101409264083100_bib14","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.3390\/cancers14123012","article-title":"Prevalence and prognostic role of IDH mutations in acute myeloid leukemia: results of the GIMEMA AML1516 protocol","volume":"14","author":"Messina","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2025101409264083100_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2021005789","article-title":"Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation","volume":"7","author":"Bill","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2025101409264083100_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2025101409264083100_bib17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41375-018-0026-z","article-title":"IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies","volume":"32","author":"Meggendorfer","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2025101409264083100_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2010-03-272146","article-title":"Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia","volume":"116","author":"Thol","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2025101409264083100_bib19","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2025101409264083100_bib20","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajh.26694","article-title":"Contemporary outcomes in IDH-mutated acute myeloid leukemia: the impact of co-occurring NPM1 mutations and venetoclax-based treatment","volume":"97","author":"Lachowiez","year":"2022","journal-title":"Am J Hematol"},{"issue":"16","key":"2025101409264083100_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2025101409264083100_bib22","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"2025101409264083100_bib23","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025101409264083100_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"21","key":"2025101409264083100_bib25","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.3390\/cancers13215431","article-title":"Molecular minimal residual disease detection in acute myeloid leukemia","volume":"13","author":"Vonk","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025101409264083100_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620715614529","article-title":"Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies","volume":"7","author":"Ommen","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"2025101409264083100_bib27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025101409264083100_bib28","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025101409264083100_bib29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/bloodadvances.2024014490","article-title":"Advantages of a genomic DNA-based next generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML","volume":"9","author":"Vonk","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"2025101409264083100_bib30","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"2025101409264083100_bib31","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv"},{"issue":"39","key":"2025101409264083100_bib32","doi-asserted-by":"crossref","first-page":"42345","DOI":"10.18632\/oncotarget.5645","article-title":"IDH1\/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association","volume":"6","author":"Debarri","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2025101409264083100_bib33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41409-023-02189-9","article-title":"Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide","volume":"59","author":"Ravindra","year":"2024","journal-title":"Bone Marrow Transpl"},{"key":"2025101409264083100_bib34","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.28.23293166","article-title":"Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia","author":"Ravindra","year":"1  2023","journal-title":"medRxiv"},{"issue":"10","key":"2025101409264083100_bib35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/fon-2017-0523","article-title":"The role of IDH mutations in acute myeloid leukemia","volume":"14","author":"Montalban-Bravo","year":"2018","journal-title":"Future Oncol"},{"key":"2025101409264083100_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clinbiochem.2018.08.012","article-title":"IDH1 and IDH2 mutations in patients with acute myeloid leukemia: suitable targets for minimal residual disease monitoring?","volume":"61","author":"Petrova","year":"2018","journal-title":"Clin Biochem"},{"issue":"7714","key":"2025101409264083100_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"2025101409264083100_bib38","doi-asserted-by":"crossref","first-page":"100587","DOI":"10.1016\/j.blre.2019.100587","article-title":"From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities?","volume":"37","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev"},{"issue":"5","key":"2025101409264083100_bib39","doi-asserted-by":"crossref","first-page":"EVIDoa2200310","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"2025101409264083100_bib40","unstructured":"Dutch-Belgian Cooperative Trial Group for Hematology-Oncology. Accessed 28 July 2025. http:\/\/www.hovon.nl."},{"key":"2025101409264083100_bib41","unstructured":"Randomized study to assess the added value of laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS \u2265 1.5). Accessed 28 July 2025. https:\/\/hovon.nl\/en\/trials\/ho92."},{"issue":"4","key":"2025101409264083100_bib42","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","article-title":"Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial","volume":"5","author":"L\u00f6wenberg","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2025101409264083100_bib43","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2016-10-740613","article-title":"Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML","volume":"129","author":"L\u00f6wenberg","year":"2017","journal-title":"Blood"},{"key":"2025101409264083100_bib44","unstructured":"Randomized induction and post induction therapy in adult patients (\u226460 yrs of age) with acute myelocytic leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score \u2265 1.5. Accessed 28 July 2025. https:\/\/hovon.nl\/en\/trials\/ho42a."},{"issue":"13","key":"2025101409264083100_bib45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2025101409264083100_bib46","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1038\/s41467-022-31397-y","article-title":"Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"2025101409264083100_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-4939-6442-0_4","article-title":"In situ single-molecule RNA genotyping using padlock probes and rolling circle amplification","volume":"1492","author":"Krzywkowski","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"7","key":"2025101409264083100_bib48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"2025101409264083100_bib49","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-022-01121-z","article-title":"Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis","volume":"54","author":"Kar","year":"2022","journal-title":"Nat Genet"},{"issue":"26","key":"2025101409264083100_bib50","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2025101409264083100_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41409-024-02447-4","article-title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2025101409264083100_bib52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41409-024-02449-2","article-title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2025101409264083100_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41375-021-01368-1","article-title":"Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration","volume":"36","author":"Cappelli","year":"2022","journal-title":"Leukemia"},{"issue":"7834","key":"2025101409264083100_bib54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"7","key":"2025101409264083100_bib55","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.CCR-23-2234","article-title":"FDA approval summary: ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation","volume":"30","author":"Woods","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025101409264083100_bib56","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17512433.2018.1477585","article-title":"Enasidenib for the treatment of acute myeloid leukemia","volume":"11","author":"Dugan","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"25","key":"2025101409264083100_bib57","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2025101409264083100_bib58","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"2025101409264083100_bib59","doi-asserted-by":"crossref","first-page":"106946","DOI":"10.1016\/j.leukres.2022.106946","article-title":"Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia","volume":"122","author":"Klink","year":"2022","journal-title":"Leuk Res"},{"issue":"1","key":"2025101409264083100_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/fon-2017-0392","article-title":"Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia","volume":"14","author":"Stein","year":"2018","journal-title":"Future Oncol"},{"issue":"2","key":"2025101409264083100_bib61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2023010563","article-title":"A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML","volume":"8","author":"Cai","year":"2024","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4860\/2414140\/blooda_adv-2025-016726-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4860\/2414140\/blooda_adv-2025-016726-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:27:51Z","timestamp":1760448471000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/4860\/546238\/Utility-of-IDH1-2-mutations-as-biomarkers-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":61,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016726","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,9,26]]}}}